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Background: TNF-like ligand 1A (TL1A), a recently recognized member of the TNF superfamily, and its death
domain receptor 3 (DR3), firstly identified for their relevant role in T lymphocyte homeostasis, are now well-known
mediators of several immune-inflammatory diseases, ranging from rheumatoid arthritis to inflammatory bowel diseases
to psoriasis, whereas no data are available on their involvement in sarcoidosis, a multisystemic granulomatous disease
where a deregulated T helper (Th)1/Th17 response takes place.
Methods: In this study, by flow cytometry, real-time PCR, confocal microscopy and immunohistochemistry analyses,
TL1A and DR3 were investigated in the pulmonary cells and the peripheral blood of 43 patients affected by sarcoidosis
in different phases of the disease (29 patients with active sarcoidosis, 14 with the inactive form) and in 8 control subjects.
Results: Our results demonstrated a significant higher expression, both at protein and mRNA levels, of TL1A and DR3 in
pulmonary T cells and alveolar macrophages of patients with active sarcoidosis as compared to patients with the
inactive form of the disease and to controls. In patients with sarcoidosis TL1A was strongly more expressed in the lung
than the blood, i.e., at the site of the involved organ. Additionally, zymography assays showed that TL1A is able to
increase the production of matrix metalloproteinase 9 by sarcoid alveolar macrophages characterized, in patients with
the active form of the disease, by reduced mRNA levels of the tissue inhibitor of metalloproteinase (TIMP)-1.
Conclusions: These data suggest that TL1A/DR3 interactions are part of the extended and complex immune-
inflammatory network that characterizes sarcoidosis during its active phase and may contribute to the pathogenesis
and to the progression of the disease.
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Sarcoidosis is a multisystemic granulomatous disease of un-
known etiology characterized by a compartmentalization of
CD4+ T helper 1 (Th1)/Th17 lymphocytes [1] and activated
monocyte/macrophages in involved organs, predominantly
the lungs [2, 3]. In the majority of patients the disease
spontaneously resolves, but in some subjects, the persist-
ence of the antigenic stimulus favors a chronic immuno-
inflammatory state, the formation of lung granulomas,* Correspondence: monica.facco@unipd.it; carlo.agostini@unipd.it
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(http://creativecommons.org/publicdomain/zeroand, in some cases, an evolution toward fibrosis [4]. A re-
dundant and complex network of cytokines and chemo-
kines directs the pathogenesis of sarcoidosis: in the early
phases, the sites of active disease are characterized by an
overproduction of Th1/Th17 cytokines, such as interleukin
(IL)-2, IFN-gamma [5], and IL-17 [1], associated with the
high expression of macrophage-derived molecules like IL-
15 [5], CXCL16 [6], CXCL10 [7], CCL20 [8], and CCL5 [9].
TNF-like ligand 1A (TL1A) and its death domain recep-
tor 3 (DR3) are members of the tumor necrosis factor
superfamily of ligands and receptors, respectively.
Well-established and emerging evidence demonstrates
the relevant impact of TL1A/DR3 signalling on the fate
of a variety of immune cells, from T helper (1, 2, andrticle distributed under the terms of the Creative Commons Attribution
es/by/4.0), which permits unrestricted use, distribution, and reproduction in
properly credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
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[10], supporting the concept that TL1A is a crucial
regulator of inflammation at the interface between the
innate and adaptive immune system [11]. Particularly,
the TL1A binding to DR3, mainly expressed on T cells,
initiates a number of immune responses culminating in
the activation of T cells and the secretion of pro-
inflammatory mediators [12]. As a consequence of
these effects, TL1A and its receptor are frequently in-
volved in the pathogenesis of many autoimmune and
inflammatory diseases, including rheumatoid arthritis
[13, 14], psoriasis [15], and inflammatory bowel dis-
eases [16, 17], most of them characterized by a Th1/
Th17 microenvironment as sarcoidosis [17–19].
Herein, we investigate the hypothesis that TL1A and
DR3 are implicate in the pathogenesis and/or evolution
of sarcoidosis by stratifying forty-three patients in differ-
ent phases of the disease and comparing them to control
subjects.
Methods
Study population
Forty-three patients with sarcoidosis were analyzed. In
all cases, the diagnosis was made from a biopsy obtained
either from the lungs or from lymph nodes and showing
non-caseating epithelioid granulomas with no evidence
of inorganic material known to cause granulomatous
diseases.
The patients underwent bronchoalveolar lavage (BAL)
fluid analysis. In particular, twenty-nine sarcoid patients
presenting with an episode of pulmonary involvement
were evaluated at the onset of the disease. They were
defined as having a high intensity alveolitis (i.e., the active
form of the disease) on the basis of the following charac-
teristics: lymphocytic alveolitis (> than 30x103 lympho-
cytes/ml); lung CD4 to CD8 ratio >4.0. The assessment of
disease activity included BAL, clinical features, chest
radiograph, lung function tests, high-resolution computed
tomography, and routine blood studies. BAL samples were
also obtained from fourteen patients with previously diag-
nosed pulmonary sarcoidosis who repeated BAL fluid ana-
lysis during their follow-up period. These patients had
normal lung function, normal BAL fluid cell numbers,
and no clinical signs of acute disease. No patient received
immunosuppressive therapy for 6 months prior to the
BAL execution.
Eight subjects were selected as controls for the BAL
studies, evaluated for cough complaints without lung
disease. They had normal physical examination, chest X
rays, lung function tests, and BAL cell numbers.
Peripheral blood from patients with sarcoidosis and
from eight healthy subjects was also included in the study.
Written informed consent was obtained from each patient
and from controls.Preparation of cell suspensions
Following administration of local anaesthesia, BAL was
performed as previously described [20]. Briefly, a total of
150–200 ml of saline solution was injected via fiber-
optic bronchoscopy, in 25 ml aliquots, with immediate
vacuum aspiration after each aliquot. The fluid was fil-
tered through gauze, and its volume was measured. The
amount of injected fluid recovered was 77.3 ± 7.5 %.
Cells recovered from the BAL fluid were washed 3 times
with PBS, resuspended in endotoxin tested RPMI 1640
(Sigma Chemical Co., St. Louis, MO) supplemented with
20 mM HEPES and L-glutamine, 100 U/ml penicillin,
100 μg/ml streptomycin, and 10 % fetal calf serum
(FCS), (ICN Flow, Costa Mesa, CA) and then counted.
Alveolar macrophages (AMs), lymphocytes, neutrophils
and eosinophils were differentially counted in cytocentri-
fuged smears stained with Wright-Giemsa, for a total
count of 300 cells, according to morphological criteria.
AMs and BAL T-cells were purified from BAL cell sus-
pensions by rosetting with neuraminidase-treated sheep
red blood cells followed by Ficoll-Hypaque gradient sepa-
rations, as previously described [1]. AMs were further
enriched by removing residual CD3+, CD16+, and CD56+
lymphocytes with magnetic separation columns (Mini-
MACS, Miltenyi Biotec), as previously described [1].
Staining with monoclonal antibodies (mAbs) showed
that, after this multistep selection procedure, >98 % of
AMs expressed the AM-associated CD68 antigen,
whereas >98 % of the rosetting population was constituted
by CD3+ T cells. CD4+ T cells were separated from CD8+
T lymphocytes by magnetic separations over columns
(Mini MACS, Sunnyvale, CA), as previously reported [1].
Peripheral blood mononuclear cells (PBMCs) from the
patients under study were obtained from freshly heparin-
ized blood following centrifugation on Ficoll-Hypaque gra-
dient and washing with PBS. Peripheral blood lymphocytes
were further enriched following rosetting of PBMC with
sheep-red-blood cells, as reported above, and CD4+ T-cells
were separated from CD8+ T lymphocytes by magnetic
separations over columns (Mini MACS).
Monoclonal antibodies and cytokines
The commercially available conjugated or unconjugated
mAbs used belonged to the Becton Dickinson and Phar-
mingen (San Diego, CA) series and included: CD3, CD4,
CD8, CD11c, CD14, CD16, CD19, CD45R0, CD45RA,
CD68, IL4 and IFN-γ, and isotype-matched controls.
Anti- mAbs were purchased from R&D Systems Inc.
(Minneapolis, MN). Purified mouse IgG1 anti-human
TL1A (clone 12 F11) was purchased from Human Genome
Sciences (GlaxoSmithKline, Verona, Italy) while mouse
IgG1 anti-human DR3/TNFRSF25 was from R&D (R&D
Systems, Milan, Italy). These mAbs were used for flow cy-
tometry and immunohistochemistry analyses. A secondary
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Laboratories, Burlingame, CA, USA) was used for flow
cytometry analysis. The frequency of positive cells for
TL1A and DR3 was determined by FACS analysis. Cells
were acquired on FACSCanto analyzer (Becton-Dickinson)
and data processed by FACSDiva software program
(Becton-Dickinson).
Confocal microscopy
T cells and AMs from BAL of patients with active (n = 4)
and inactive (n = 4) sarcoidosis and controls (n = 3) were
plated in polylisine coated glass for 15 min at +4 °C,
with anti-TL1A (1:150) and anti-DR3 (1:150) mAbs, and
fixed in 4 % paraformaldehyde for 10 min. To reveal
positivity for the molecules, a FITC-conjugated rat anti-
mouse IgG1 (1:200) was used. Background staining with
FITC-conjugated rat anti-mouse IgG1 alone was rou-
tinely compared with positively stained cells and was not
visible using identical acquisition settings.
Slides were mounted with cover slips and fluorescence
was detected using the UltraView LCI confocal system
equipped with a fluorescence filter set for excitation at
488 nm.
Western blot analysis
BAL cells (0.25 × 106 for each sample) purified from 8
patients affected by active sarcoidosis, 7 patients with in-
active disease, and 8 controls, were prepared by cell lyses
with Tris 20 mM, NaCl 150 mM, EDTA 2 mM, EGTA
2 mM, Triton X-100 0.5 % supplemented with complete
protease inhibitor cocktail (Roche; Mannheim, Germany)
and sodium orthovanadate 1 mM (Calbiochem; Gibbs-
town, NJ). Samples were then subjected to SDS/PAGE
(10 % gels), transferred to nitrocellulose membranes, and
immunostained with goat polyclonal Ab anti-human
TL1A/TNFS15 (R&D Systems Inc.), mouse mAb anti-
human DR3/TNFRSF25 (R&D Systems Inc.), and
mouse mAb anti-human β-actin (Sigma-Aldrich),
using an enhanced chemiluminescent detection system
(Pierce; Rockford, IL).
Immunohistochemical analysis
Lung samples from eight cases of sarcoidosis (five from
active, three from inactive forms, the last obtained from
native lungs of patients requiring lung transplantation)
were processed by immunohistochemistry.
Briefly four μm-thick sequential serial sections were pre-
treated by boiling in citrate buffer (pH 6.1) in a microwave
(700 W, 1 minute) for antigen retrieval. Afterwards, sec-
tions were treated with normal serum (Immunotech,
Marseille, France) and incubated for 60 min with the pri-
mary monoclonal antibodies anti-IL 17 and anti-IL23R at
a concentration of 1:20 and 1:50. Sections were subse-
quently incubated with rabbit horseradish peroxidase(HRP) polymer (Dako, Glostrup, Denmark) for 30 min.
Immunoreactivity was visualized with 3-3’-diaminobenzi-
dine (DAB, Dako, Glostrup, Denmark). Negative controls
for non-specific binding were processed omitting the
primary antibodies and revealed no signal.
Real-Time PCR expression analysis
Total cellular RNA was extracted from cells using the
RNeasy Mini Kit (Qiagen, Hilden, Germany) according
to the manufacturer’s protocol and was treated with
DNase (Qiagen). Complementary DNA was generated
from 1 μg of total RNA using oligo-dT primer and the
AMV reverse transcriptase (Promega, Madison, WI).
Real-time PCR was carried out in an ABI Prism 7000 se-
quence detection system (Applied Biosystems, Foster
City, CA). SYBR Green PCR Master Mix was purchased
from Applied Biosystems. Real-Time PCR for TL1A,
DR3, MMP-9 and TIMP-1 gene expression was per-
formed in purified AMs and BAL T cells of patients with
active (n = 25) and inactive sarcoidosis (n = 13). TL1A
and DR3 mRNA levels were also evaluated in monocytes
and T cells from the peripheral blood of the same pa-
tients and 8 healthy controls. The primers used were:
TL1A: forward 5’-CAC CTC TTA GAG CAG ACG
GAG ATA A-3’, reverse 5’-TTA AAG TGC TGT GTG
GGA GTT TGT-3’; DR3: forward 5’-ACC CAT CTG
TCA CCC TTG GA-3’, reverse 5’-CTG GAC GGT GCA
GAT CTT CTC-3’; MMP-9: forward 5’-TGC CCG GAC
CAA GGA TAC AG-3’, reverse 5'- GTG CAT TCC TCA
CAG CCA ACA G; glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH): forward 5’-AAT GGA AAT
CCC ATC ACC ATC T-3’; reverse 5’-CGC CCC ACT
TGA TTT TGG-3’. The primers were designed in our
laboratory, whereas for TL1A we used the primers as
described by Migone et al. [21]. Standard curves were gen-
erated for each gene. The relative amounts of messenger
RNA (mRNA) were normalized for GAPDH expression.
Gelatin zymography assays
This is an in vitro assay using gelatin-substrate gel elec-
trophoresis we employed to measure the level of MMP-
9 activity in BAL fluid components or in 24 h culture
medium recovered from AMs and lung T cells, of pa-
tients with active (n = 7) and inactive (n = 6) sarcoidosis,
cultured with or without TL1A (100 ng/ml, R&D Sys-
tems). BAL fluid components and conditioned superna-
tants were mixed with an equal volume of sample buffer
(62.5 mM Tris–HCl, pH 6.8, 10 % glycerol, 2 % SDS,
and 0.00625 % (w/v) bromophenol blue). Samples were
electrophoresed on 7.5 % SDS polyacrylamide gel con-
taining 2 mg/mL gelatin (type A, Sigma-Aldrich). After
electrophoresis, the gel was washed three times for
30 min in 2.5 % Triton X-100 at room temperature, and
incubated for 16 h at 37 °C in incubation buffer (50 mM
Table 1 Clinical characteristics of patients with sarcoidosis
Patients with active sarcoidosis (n = 29)
Stage 1 (bilateral hilar lymphadenopathy) 13
Stage 2 (bilateral hilar lymphadenopathy
with pulmonary infiltrates)
11
Stage 3 (parenchymal infiltrates without
hilar adenopathy)
5
FVC% 103.33 ± 11.60
FEV1% 101.16 ± 14.76
DLCO% 79.33 ± 11.13
TIFF 92.00 ± 12.94
Patients with inactive sarcoidosis (n = 14)
Stage 1 11
Stage 2 3
Stage 3 0
FVC% 98.20 ± 15.39
FEV1% 93.10 ± 17.99
DLCO% 86.77 ± 10.72
TIFF 80.01 ± 8.99
FVC, Forced vital capacity; FEV1, Forced Expiratory Volume in the first second;
DLCO, Diffusing Capacity of the Lung for Carbon Monoxide; TIFF, Tiffeneau index
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was stained for 30 min with Coomassie Brilliant Blue R-
250 (Amersham Biosciences) and destained in washing
solution (30 % methanol, 10 % acetic acid). White bands
on the blue background represented gelatin digestion
corresponding to the presence/activity of MMP-9. The
bands were quantified by the image analysis software
QuantityOne (Bio-Rad).
Statistical analysis
Statistical analysis was performed using Student's t test,
Kolgomorov-Smirnov analysis, and ANOVA. Data were
expressed as mean ± standard deviation (SD) and were con-
sidered statistically significant when p values were <0.05.
Results
Patient characteristics
Twenty-nine subjects with high intensity alveolitis were
evaluated at the onset of the disease (19 men and 10
women; mean age 42.5 ± 12.9 years; 7 smokers). Twenty-
six patients required corticosteroid therapy; three pa-
tients spontaneously resolved. Fourteen patients (5 men
and 9 women; mean age 40.5 ± 12.5 years; 2 smokers),
with previously diagnosed pulmonary sarcoidosis, re-
peated BAL fluid analysis during their follow-up period
(follow-up period average: 57.1 ± 18.6 months, range
from 33–81 months). Further characteristics of patients
studied are shown in Table 1. Eight subjects were se-
lected as controls for the BAL studies (6 men and 2
women; mean age 37.5 ± 4.3 years; nonsmokers).
Morphological and phenotypical analyses
Morphological and phenotypical features of cells ob-
tained from the BAL of patients with sarcoidosis and
eight control subjects are reported in Table 2. All sub-
jects with active sarcoidosis showed a high intensity
CD4+ lymphocytic alveolitis sustained by CD45RO+ T
cells. The majority of these cells were equipped with the
chemokine receptor CXCR3, IL-12Rβ, and intracytoplas-
matic IFN-γ (data not shown). CD4+ and CD8+ T cell
subsets and AMs detected in the BAL of patients with
inactive sarcoidosis were superimposable to those ob-
served in controls (Table 2).
TL1A and DR3 expression in lung T cells and alveolar
macrophages from patients with sarcoidosis
By flow cytometry, we investigated the presence of TL1A
and DR3 on freshly obtained pulmonary and peripheral
blood cells of patients with active and inactive sarcoidosis,
and controls.
As shown in Fig. 1a, the percentage of freshly obtained
pulmonary CD4+ T lymphocytes expressing TL1A was
much higher in patients with the active form of the dis-
ease (20.3 % ± 6.3), as compared to inactive sarcoidosis(9.4 % ± 4.5 of CD4+ T cells; p < 0.01 vs active disease),
and to controls (1.7 % ± 1.5 of CD4+ T lymphocytes; p <
0.01 vs active disease; ANOVA p < 0.01). CD8+ T cells
showed a similar expression, characterized by more
raised TL1A levels in patients with active sarcoidosis
(17.3 % ± 4.9), as compared to inactive disease (7.7 % ±
4.7 of CD8+ T cells; p < 0.01 vs active disease), and to
controls (2.4 % ± 1.6 of CD8+ T lymphocytes; p < 0.01 vs
active disease; ANOVA p < 0.01). In addition, AMs were
marked by a decreasing expression of TL1A from pa-
tients with the active form of disease (15.2 % ± 3.6), to
inactive sarcoidosis (7.3 % ± 3.5 of AMs; p < 0.01 vs ac-
tive disease), to controls (4.8 % ± 2.1 of AMs; p < 0.01
vs active disease; ANOVA p < 0.01) (Fig. 1a). Peripheral
T cell populations and monocytes of patients and con-
trols were characterized by low (with respect to lung)
but, among them, comparable TL1A expressions, with-
out any statistical difference (Fig. 1a). Mean fluores-
cence intensity (MFI) results, related to the amount of
protein locates on cell surface, parallel the trends of
TL1A expression in each different cell subset (data not
shown).
As far as DR3 is concerned (Fig. 1b), lung CD4+ T
cells obtained from patients with active sarcoidosis
expressed the receptor in a percentage significantly
higher (33.2 % ± 7.1) with respect to pulmonary CD4+ T
cells of patients with inactive sarcoidosis (15.4 % ± 5.3;
p < 0.01 vs active disease), and controls (10.6 % ± 4.1; p <
0.01 vs active disease; ANOVA p < 0.01; Fig. 1b). No
relevant differences were found in DR3 expression by
Table 2 BAL characteristics of sarcoid patients and control subjects
Cell recovery Alveolar macrophages Lymphocytes CD4+ T cells CD8+ T cells
x 103/ml x 103/ml % x 103/ml % x 103/ml % x 103/ml %
active sarcoidosis (n: 29) 300 ± 37 208 ± 51 76 ± 10 79 ± 35 24 ± 9 69 ± 12 83 ± 7 13 ± 8 19 ± 6
inactive sarcoidosis (n: 14) 110 ± 23 109 ± 26 96 ± 4 6 ± 5 5 ± 2 4 ± 3 58 ± 2 3 ± 1 37 ± 4
controls (n: 8) 115 ± 17 111 ± 24 94 ± 3 5 ± 4 6 ± 3 4 ± 2 58 ± 6 3 ± 2 39 ± 7
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sarcoidosis 17.0 % ± 4.7; controls: 14.6 % ± 5.8, of CD8+ T
cells; p: not significant), whereas AMs from patients with
active sarcoidosis were marked out by the highest DR3 ex-
pression (36.0 % ± 11.7) as compared to inactive sarcoid-
osis (12.2 % ± 7.1 of AMs; p < 0.01 vs active disease), and
to controls (11.3 % ± 3.8 of AMs; p < 0.01 vs active disease;
ANOVA p < 0.01) (Fig. 1b).Fig. 1 Flow cytometry analyses of TL1A (a) and DR3 (b) expression evaluated i
freshly obtained from the lung and the blood of patients affected by act
and from control subjects (white columns). Data are expressed as mean ±In the peripheral blood, CD4 and CD8 T cell subsets
and monocytes of patients and controls showed similar
DR3 expression, with no significant differences (Fig. 1b).
As well as for TL1A, MFI data concerning DR3 followed
the trend of the results described above (data not shown).
Western blotting (Fig. 2a) and confocal microscopy ana-
lyses (Fig. 2b) of TL1A and DR3 confirmed the higher ex-
pression of the two molecules on lung T lymphocytes andn T (CD4+ and CD8+) lymphocytes and alveolar macrophages/monocytes
ive sarcoidosis (black columns), inactive sarcoidosis (grey columns),
SD
Fig. 2 Western blotting (a) and confocal microscopy (b) analyses of TL1A and DR3 proteins evaluated in lung T cells and alveolar macrophages
obtained from the BAL of two representative cases of patients with active and inactive sarcoidosis and of a control subject. (c) TL1A and DR3
mRNA expression in CD4+ T lymphocytes and alveolar macrophages/monocytes freshly obtained from the lung and the blood of patients
affected by active sarcoidosis (black columns), inactive sarcoidosis (grey columns), and from control subjects (white columns). Expression of TL1A
and DR3 mRNAs was normalized on GAPDH mRNA. Data are expressed as mean ± SD
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sarcoidosis with respect to patients with the inactive form
of the disease and to controls.
Molecular analysis of TL1A and DR3 expression
As shown in Fig. 2c, real-time polymerase chain reaction
evaluation of TL1A gene expression by highly purifiedBAL and blood CD4+ T lymphocytes, AMs and mono-
cytes, demonstrated that mRNA expression of TL1A
was higher in lung CD4+ T lymphocytes (2.2 ± 1.3) and
AMs (3.5 ± 1.6) of active sarcoidosis than in the corre-
sponding cell subsets derived from patients with inactive
disease (CD4+ T cells: 0.46 ± 0.16; AMs: 0.64 ± 0.3; p <
0.01 vs active disease), and control subjects (CD4+ T cells:
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ANOVA p < 0.01). Peripheral cell subsets of patients and
controls were characterized by comparable TL1A mRNA
expressions (p: not significant), (Fig. 2c).
Similarly, a real-time PCR evaluation of DR3 gene expres-
sion demonstrated that DR3 mRNA level was higher in
lung CD4+ T lymphocytes (2.74 ± 1.2), and especially in
AMs (9.40 ± 2.4) of active sarcoidosis than in the equivalent
cell populations of patients with inactive disease (CD4+ T
cells: 0.66 ± 1.2; p < 0.001 vs active disease; AMs: 4.4 ± 1.6;
p < 0.01 vs active disease), and control subjects (CD4+ T
cells: 0.78 ± 0.25; p < 0.001 vs active disease; AMs: 3.2 ± 2.0;
p < 0.01 vs active disease). Again, no significant differences
in DR3 mRNA expression stood out among peripheral cell
subsets of patients and controls (p: not significant).Fig. 3 Immunohistochemistry for TL1A and DR3 expression in representativ
fibrosis (C, D). A, B. TL1A and DR3 are expressed at high intensity by macro
infiltrating the lung biopsy of the patient with active sarcoidosis. The black
specimen obtained from a patient with refractory sarcoidosis and pulmona
a weak immunostaining was only seen in some epitheliod cells (arrows). N
magnification 400xTL1A and DR3 localization at sites of disease activity
Immunohistochemical analysis confirmed the expression
of TL1A and its receptor DR3 by sarcoid pulmonary T
cells infiltrating surgical pulmonary biopsies obtained
from two patients with active sarcoidosis (Fig. 3a and b).
When the cell sources of TL1A in sarcoid tissue was
investigated, we showed that the cytokine was preferen-
tially expressed by macrophage multinucleated giant
cells and T cells in the granuloma, even if endothelial
and metaplastic epithelial cells bore the two molecules.
Immunohistochemical analysis of biopsies from one pa-
tient with refractory sarcoidosis and pulmonary fibrosis
showed that lung T cells were mainly nonreactive for
TL1A and DR3, whereas some epitheliod cells were
weakly positive (Fig. 3c and d).e patients with active (A, B) and refractory sarcoidosis and pulmonary
phagic, both epitheliod and multinucleated, cells and lymphocytes
arrows indicate positive metaplastic epithelial cells. C, D. In the lung
ry fibrosis, pulmonary cells were mainly non reactive for TL1A and DR3;
ote marked fibrosis around the granulomatous nodule. Original
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macrophages
In presence of IFN-γ, TL1A increases MMP-9 produc-
tion in the human monocytic cell line THP-1 [22]. Since
IFN-γ is one of the prevalent cytokines in the lung of pa-
tients with active sarcoidosis [5], by gelatin zymography
assays we evaluated MMP-9 activity in the lung of our
patients.
As shown in Fig. 4a, panel a, BAL fluids from patients
with active sarcoidosis were characterized by a stronger
MMP-9 activity (12.5 ± 5.8) as compared to those ob-
tained from inactive sarcoidosis (3.6 % ± 1.3; p < 0.05).
AM and T cell subset isolation (Fig. 4a, panel b) demon-
strated that the source responsible of MMP-9 activityFig. 4 A. Gelatin zymograms of MMP-9 activity in the BAL fluid (a), and in
cells) (b), of two representative cases of patients with active and inactive sa
cells (d) obtained from the BAL of two representative cases of patients wit
the cytokine TL1A. B) MMP-9 activity of alveolar macrophages obtained fro
and inactive sarcoidosis (grey columns), freshly isolated, cultured in medium
were quantified by densitometry. Data are expressed as mean ± SD. D) MM
from the lung of patients affected by active sarcoidosis (black columns) an
medium alone and with TL1A. Expression of MMP-9 and TIMP-1 mRNAs wawas represented by AMs (2.8 ± 0.35 and 22.5 ± 3.8 in
AMs from inactive and active sarcoidosis, respectively;
p < 0.01 vs active disease). Successively, purified AMs
and T lymphocytes were cultured in presence (and ab-
sence) of TL1A to investigate its possible effects on MMP-
9 production and activity. Figure 4a (panel c and d), and
4B showed that MMP-9 activity referable to lung T cells
was not up-regulated by TL1A/DR3 interactions, whereas
AMs obtained from patients with inactive sarcoidosis pre-
sented an appreciable increase of the metalloproteinase
activity (3.56 ± 0.27 and 6.40 ± 1.75, in absence and pres-
ence of TL1A, respectively; p < 0.05). We did not detect
any relevant change in MMP-9 activity of AMs derived
from patients with active sarcoidosis in presence of TL1Afreshly isolated BAL cellular components (alveolar macrophages and T
rcoidosis. c, d) MMP-9 activity of alveolar macrophages (c) and lung T
h active and inactive sarcoidosis, cultured in medium alone and with
m the lung of patients affected by active sarcoidosis (black columns)
alone and with TL1A. Zymographic band densities from all samples
P-9 and TIMP-1 mRNA expression in alveolar macrophages obtained
d inactive sarcoidosis (grey columns), freshly isolated, cultured in
s normalized on GAPDH mRNA. Data are expressed as mean ± SD
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TL1A, respectively; p: not significant), probably due to an
already achieved peak of MMP-9 production and release
by these strongly activated macrophages.
Molecular analysis of MMP-9 and TIMP-1 expression
As shown in Fig. 4c, real-time PCR evaluation of MMP-9
gene expression by purified AMs demonstrated that
MMP-9 mRNA expression levels were higher in freshly
isolated AMs from patients with active sarcoidosis
(10.17 ± 4.2) compared with the corresponding AMs
from patients with the inactive form of the disease
(1.93 ± 0.89; p < 0.01 vs active disease). As verified for
MMP-9 activity, the presence of TL1A in the culture
medium of AMs from patients with active sarcoidosis
did not induce any variation in MMP-9 mRNA levels
(9.8 ± 4.0 and 9.7 ± 3.9, in absence and presence of TL1A,
respectively; p: not significant), whereas AMs recovered
from patients with inactive sarcoidosis responded to TL1A
stimulus, raising MMP-9 mRNA levels from 2.3 ± 0.8 to
4.3 ± 0.7 (in absence and presence of TL1A, respectively;
p < 0.05).
Using real-time PCR, we evaluated the tissue inhibitor
of metalloproteinase (TIMP)-1 gene expression by puri-
fied AMs of patients with active and inactive sarcoidosis
(Fig. 4c). Interestingly, we found that AMs from patients
with inactive sarcoidosis showed higher TIMP-1 mRNA
amounts with respect to AMs from active disease (1.1 ±
0.3 and 2.9 ± 0.9, in inactive and active sarcoidosis, re-
spectively; p < 0.01). When AMs were cultured with
TL1A, TIMP-1 mRNA levels significant decreased only
in AMs obtained from patients with inactive sarcoidosis
(3.1 ± 1.1 and 1.8 ± 0.3, in absence and presence of
TL1A, respectively; p < 0.05), whereas we did not point
out any variation of TIMP-1 mRNA levels in AMs ob-
tained from patients with active sarcoidosis (1.2 ± 0.3
and 1.1 ± 0.4, in absence and presence of TL1A, respect-
ively; p: not significant).
Discussion
In this report we provided evidence that cytokine TL1A
and its receptor DR3 are expressed on pulmonary T cells
and alveolar macrophages of patients with sarcoidosis,
showing their highest expression in lung cells obtained
from patients with the active form of the disease, and
when localized around and inside the granuloma or, in
general terms, at the sites of disease activity.
The pulmonary microenvironment of patients with
sarcoidosis is characterized by a well-known highly po-
larized Th1/Th17 profile [1, 6], where cytokines such as
IFN-γ, TNF-α, IL-2, IL-12, IL-17, IL-18, together with
several chemokines, induce and maintain an inflamma-
tory state further exacerbated by the constant recruit-
ment of immune cells into the lung. Cell subsets andcytokine patterns dominating sarcoid lung environment
are in line with immunologic conditions that are needed
for the expression and the activity of the TL1A/DR3 sys-
tem. In particular, TL1A expression is known to be stim-
ulated by pro-inflammatory cytokines [21] which are
known to be secreted in sarcoid lung; furthermore, DR3,
usually mainly restricted to T lymphocytes [10], was
expressed at high degree by T cells as sarcoid AMs.
TL1A engagement of DR3 results in functional signal-
ling that may induce pro-inflammatory effects [21], such
as memory CD4+ T cell secretion of pro-inflammatory cy-
tokines (IFN-γ, TNF-α, IL-17) [23, 24], Th17 cell differen-
tiation and proliferation [25], and the proliferation of
regulatory T cells with an attenuated, although still de-
bated, suppressive activity [26, 27]. These effects exactly
reflect typical phenomena taking place in the lung during
the sarcoid inflammatory process, which is characterized
by a) the presence of activated CD45RO+/CD4+ T lym-
phocytes secreting pro-inflammatory cytokines and
chemokines, b) the infiltration of Th17 cells function-
ally equipped and releasing IL-17 cytokine [1], and c)
the increase of Treg cells that display poor suppressive
capacity [28]. With this as a background we propose
that the TL1A/DR3 axis may represent an important
mediator of the chronic inflammation taking place in
the lung of patients with sarcoidosis, similarly to what
has been recently demonstrated in other Th1/Th17
chronic disorders as Chron’s disease, in which TL1A/DR3
account for IFN-γ and IL-17 increasing, intestinal Treg
proliferation, and, in a murine model, for the development
of collagen deposition [29].
We have also demonstrated that sarcoid AMs per se
produce elevated levels of metalloproteinase (MMP)-9, a
molecule belonging to a family of extracellular and cell
surface-associated proteinases, implicated in tissue
homeostasis, host defence and tissue repair also in sar-
coidosis [30, 31]. Interestingly, TL1A and DR3 stimula-
tion was able to increase the production of MMP-9 by
AMs of patients with inactive sarcoidosis, while macro-
phages derived from the lung of patients with the active
form of the disease did not vary MMP-9 production
after TL1A stimulation. Since at basal conditions sarcoid
AM per se show elevated MMP-9 production and activ-
ity, we hypothesize that AMs reached their plateau in
terms of MMP-9 production and could not be further
stimulated.
There are a number of data implicating MMPs in the
development of tissue remodelling and fibrosis that may
be observed in various inflammatory conditions [32, 33].
Fibrosis represents the irreversible phase of sarcoidosis
[34]. In some patients, the persistence of the chronic in-
flammatory response, in addition to the failure of
immune-regulatory mechanisms, leads to the invasion of
pulmonary tissues by granulomas. In turn this favours
Facco et al. Clinical and Molecular Allergy  (2015) 13:16 Page 10 of 11the definitive derangement of alveolar structures with re-
sultant fibrosis. In fact, sarcoid granulomas are known
to promote a local exaggerated production of collagen
and extracellular matrix, associated with an aberrant
fibroblast migration and proliferation. The increasing of
MMP-9 production induced by TL1A on sarcoid AMs
might exacerbate these phenomenas contributing to the
evolution of sarcoidosis towards its irreversible phase.
The MMP-9 high levels characterizing AMs from pa-
tients with active sarcoidosis paralleled the reduced
mRNA amounts of its major inhibitor, TIMP-1. This
suggests a shift in the delicate balance between the en-
zyme and its inhibitor, increasing this imbalance the
risk of intra-alveolar fibrosis development. A similar
condition marked by an increase in MMP-9 with re-
spect to low levels of TIMP-1 has been linked to the
asthma pathogenesis, particularly to explain the in-
creased presence of submucosal fibrosis in asthmatic
airways [35, 36]Conclusions
Our data highlight the presence of TL1A/DR3 axis in the
lung of patients with sarcoidosis, particularly in those pa-
tients with the active form of the disease. On the basis of
these findings it might be suggested that TL1A and DR3,
favoring the production of MMP-9 by sarcoid AMs,
further strengthen the inflammatory vicious loop take
place in sarcoid lung, thus worsening the evolution of
the disease and/or potentially delaying/compromising
its resolution.
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